Your session is about to expire
← Back to Search
Study Summary
This trial will study the long-term effects of PF-06823859 in adults with DM.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a medical or mental condition, or recent thoughts of harming yourself, that may make it risky for you to participate in the study.You stopped participating in the previous qualifying studies for any reason.You are currently experiencing a safety issue from a previous study that hasn't been resolved yet.You are between 18 and 80 years old and have moderate to severe dermatomyositis.
- Group 1: Anti-Beta Interferon drug (PF-06823859)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the eligibility criteria of this trial restricted to individuals over 55 years old?
"The primary requirement for entry in this experiment is to be over 18 and under 80 years old."
Are there any open enrolment slots in the current trial?
"According to the clinicaltrials.gov records, this medical trial is no longer recruiting patients--the original posting was on December 20th 2021 and it last edited November 17th 2022. Fortunately, there are currently 23 other trials actively seeking participants."
Has the FDA granted approval for Anti-Beta Interferon (PF-06823859)?
"Our team at Power determined that the safety of Anti-Beta Interferon (PF-06823859) should be rated as a 2, due to having some existing evidence in favor of its security, but lacking any concerning efficacy."
How extensive is the geographic coverage of this research endeavor?
"This clinical research is enrolling patients in KU Clinical and Translational Science Unit (CTSU) Rainbow located in Scottsdale, Arizona; Mayo Clinic found in New york City; Mount Sinai Doctors Dermatology situated near Boston, Massachusetts as well as other 23 sites."
What criteria must be met to qualify for participation in this trial?
"To be eligible, candidates must suffer from dermatomyositis and fall within the age range of 18 to 80. The trial is looking for 24 individuals in total."
Share this study with friends
Copy Link
Messenger